Anti-Hu CD49d Purified

*Stenner MP, Waschbisch A, Buck D, Doerck S, Einsele H, Toyka KV, Wiendl H: Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS One. 2008 Oct 6;3 (10) :e3319. , URL: http://www.ncbi.nlm.nih.gov/pubmed/18836525, *Chigaev A, Waller A, Amit O, Halip L, Bologa CG, Sklar LA: Real-time analysis of conformation-sensitive antibody binding provides new insights into integrin conformational regulation. J Biol Chem. 2009 May 22;284 (21) :14337-46, URL: http://www.ncbi.nlm.nih.gov/pubmed/19251697 , *Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, Sorokin L, Vestweber D, Zarbock A, Schwab N, Wiendl H: VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. J Exp Med. 2014 Aug 25;211 (9) :1833-46., URL: https://pubmed.ncbi.nlm.nih.gov/25135296/, *Yoon SO, Lee IY, Zhang X, Zapata MC, Choi YS: CD9 may contribute to the survival of human germinal center B cells by facilitating the interaction with follicular dendritic cells. FEBS Open Bio. 2014 Apr 13;4:370-6. , URL: http://www.ncbi.nlm.nih.gov/pubmed/24918051 , *Zhang XF, Feng MF: Adherence of human monocytes and NK cells to human TNF-alpha-stimulated porcine endothelial cells. Immunol Cell Biol. 2000 Dec;78 (6) :633-40., URL: http://www.ncbi.nlm.nih.gov/pubmed/11114974 , *Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER: The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330 (3) :864-75., URL: https://pubmed.ncbi.nlm.nih.gov/19509315/